Methods of treating mesothelioma with suberoylanilide hydroxamic acid

1. A method of treating mesothelioma in a subject, said method comprising the step of administering to the subject an effective amount of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA), represented by the structure:

or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier or diluent, in an amount effective to treat mesothelioma in said subject.

2. The method of claim 1 , wherein the pharmaceutical composition is administered orally.

3. The method of claim 2 , wherein said composition is contained within a gelatin capsule.

4. The method of claim 3 , wherein said carrier or diluent is microcrystalline cellulose.

5. The method of claim 4 , further comprising sodium croscarmellose as a disintegrating agent.

6. The method of claim 5 , further comprising magnesium stearate as a lubricant.

7. The method of claim 2 , wherein said composition is administered to the subject at a total daily dosage of between about 25–4000 mg/m 2 .

8. The method of claim 2 , wherein said composition is administered once-daily, twice-daily or three times-daily.

9. The method of claim 8 , wherein said composition is administered once daily at a dose of about 200–600 mg.

10. The method of claim 8 , wherein said composition is administered twice daily at a dose of about 200–400 mg.

11. The method of claim 8 , wherein said composition is administered twice daily at a dose of about 200–400 mg intermittently.

12. The method of claim 11 , wherein said composition is administered three to five days per week.

13. The method of claim 11 , wherein said composition is administered three days a week.

14. The method of claim 13 , wherein said composition is administered at a dose of about 200 mg.

15. The method of claim 13 , wherein said composition is administered at a dose of about 300 mg.

16. The method of claim 13 , wherein said composition is administered at a dose of about 400 mg.

17. The method of claim 2 , wherein said composition is administered three times-daily.

18. A method of treating mesothelioma in a subject, said method comprising the step of administering orally to the subject an effective amount of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) or a pharmaceutically acceptable salt or hydrate thereof, represented by the structure:

and a pharmaceutically acceptable carrier or diluent, wherein the amount of SAHA is effective to treat mesothelioma in said subject.

19. The method of claim 18 , wherein said composition is contained within a gelatin capsule.

20. The method of claim 19 , wherein said carrier or diluent is microcrystalline cellulose.

21. The method of claim 20 , further comprising sodium croscarmellose as a disintegrating agent.

22. The method of claim 21 , further comprising magnesium stearate as a lubricant.

23. The method of claim 18 , wherein said composition is administered to the subject at a total daily dosage of between about 25–4000 mg/m 2 .

24. The method of claim 18 , wherein said composition is administered once-daily, twice-daily or three times-daily.

25. The method of claim 24 , wherein said composition is administered once daily at a dose of about 200–600 mg.

26. The method of claim 24 , wherein said composition is administered twice daily at a dose of about 200–400 mg.

27. The method of claim 26 , wherein said composition is administered at a dose of about 200 mg.

28. The method of claim 26 , wherein said composition is administered at a dose of about 300 mg.

29. The method of claim 26 , wherein said composition is administered at a dose of about 400 mg.

30. The method of claim 24 , wherein said composition is administered twice daily at a dose of about 200–400 mg intermittently.

31. The method of claim 30 , wherein said composition is administered three to five days per week.

32. The method of claim 30 , wherein said composition is administered three days a week.

33. The method of claim 32 , wherein said composition is administered at a dose of about 200 mg.

34. The method of claim 32 , wherein said composition is administered at a dose of about 300 mg.

35. The method of claim 32 , wherein said composition is administered at a dose of about 400 mg.

36. The method of claim 30 , wherein said composition is administered at a dose of about 200 mg.

37. The method of claim 30 , wherein said composition is administered at a dose of about 300 mg.

38. The method of claim 30 , wherein said composition is administered at a dose of about 400 mg.

39. The method of claim 18 , wherein said composition is administered three times-daily.

40. A method of treating mesothelioma in a subject, said method comprises the step of administering to the subject a total daily dose of up to about 800 mg of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) or a pharmaceutically acceptable salt or hydrate thereof, represented by the structure:

and a pharmaceutically acceptable carrier or diluent, wherein the mesothelioma in said subject is treated.

41. The method of claim 40 , wherein the pharmaceutical composition is administered orally.

42. The method of claim 41 , wherein said composition is contained within a gelatin capsule.

43. The method of claim 42 , wherein said carrier or diluent is microcrystalline cellulose.

44. The method of claim 43 , further comprising sodium croscarmellose as a disintegrating agent.

45. The method of claim 44 , further comprising magnesium stearate as a lubricant.

46. The method of claim 41 , wherein said composition is administered once-daily, twice-daily or three times-daily.

47. The method of claim 46 , wherein said composition is administered once daily at a dose of about 200–600 mg.

48. The method of claim 46 , wherein said composition is administered twice daily at a dose of about 200–400 mg.

49. The method of claim 46 , wherein said composition is administered twice daily at a dose of about 200–400 mg intermittently.

50. The method of claim 49 , wherein said composition is administered three to five days per week.

51. The method of claim 49 , wherein said composition is administered three days a week.

52. The method of claim 51 , wherein said composition is administered at a dose of about 200 mg.

53. The method of claim 51 , wherein said composition is administered at a dose of about 300 mg.

54. The method of claim 51 , wherein said composition is administered at a dose of about 400 mg.

55. The method of claim 41 , wherein said composition is administered three times-daily.